Kathleen Blair, DO
Internal Medicine · Great Falls, MTNPI 1346335189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $424 and has fallen 58.4% since, to $176 in 2025. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$303
- Corcept Therapeutics$142
- E.r. Squibb & Sons, L.L.C.$136
- Amgen$109
- Novartis$88
- AstraZeneca$84
- plus $448 from 15 others
What the payments were for
- Food & beverage$1,309100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $303 |
| Corcept Therapeutics | 4 | $142 |
| E.r. Squibb & Sons, L.L.C. | 9 | $136 |
| Amgen | 6 | $109 |
| Novartis | 5 | $88 |
| AstraZeneca | 5 | $84 |
| Astellas Pharma US Inc | 3 | $65 |
| Novo Nordisk | 3 | $55 |
| Merck | 3 | $45 |
| Exact Sciences | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $34 |
| Pfizer | 2 | $29 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Verona Pharma, Inc. | 1 | $20 |
| Bayer | 1 | $17 |
| AbbVie | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,309 in reported general payments places this provider in the 90th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 163 | $163,239 |
| OzempicSemaglutide | 80 | $105,779 |
| MounjaroTirzepatide | 73 | $92,602 |
| JanuviaSitagliptin Phosphate | 87 | $78,553 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $39,572 |
| FarxigaDapagliflozin Propanediol | 30 | $34,432 |
| XareltoRivaroxaban | 30 | $29,546 |
| MyrbetriqMirabegron | 33 | $25,561 |
| Spiriva RespimatTiotropium Bromide | 28 | $18,788 |
| WegovySemaglutide | 12 | $18,033 |
| LinzessLinaclotide | 21 | $16,387 |
| TrulicityDulaglutide | 11 | $16,079 |
| JardianceEmpagliflozin | 16 | $11,826 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $11,465 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $163,239163 claims |
| Novo NordiskOzempic, Wegovy | $55 | $123,81292 claims |
| MerckJanuvia | $45 | $78,55387 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $303 | $55,22377 claims |
| AstraZenecaFarxiga, Symbicort | $84 | $39,61245 claims |
| Johnson & JohnsonXarelto | $13 | $29,54630 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $25,56133 claims |
| AbbVieLinzess, Synthroid | $14 | $18,50948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Great Falls
- Stacy KingslandGreat Falls$5K
- Nicholas TrumGreat Falls$2K
- Bradford BergmanGreat Falls$2K
- Steven ChrzanowskiGreat Falls$2K
- Scott BurkGreat Falls$1K
- Katherine ZitelloGreat Falls$682
- Eve GerasimouGreat Falls$661
- Berilonson OsiroGreat Falls$340
- James LeganGreat Falls$312
- Hanna BroniewskaGreat Falls$193
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.